206 related articles for article (PubMed ID: 34547468)
21. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
[No Abstract] [Full Text] [Related]
22. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
[TBL] [Abstract][Full Text] [Related]
23. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
24. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
26. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
27. Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
Kamiya H; Komatsu S; Takashima Y; Ishida R; Arakawa H; Nishibeppu K; Kiuchi J; Imamura T; Ohashi T; Shimizu H; Arita T; Konishi H; Shiozaki A; Kubota T; Fujiwara H; Yagyu S; Iehara T; Otsuji E
Br J Cancer; 2024 Mar; 130(4):671-681. PubMed ID: 38148376
[TBL] [Abstract][Full Text] [Related]
28. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
He PX; Ma ZL; Han H; Zhang XY; Niu SH; Du LN; Zheng YC; Liu HM
Life Sci; 2020 Feb; 242():117247. PubMed ID: 31899223
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
[No Abstract] [Full Text] [Related]
31. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
Sughayer MA; Dabbagh TZ; Battah AH
Appl Immunohistochem Mol Morphol; 2020; 28(10):748-754. PubMed ID: 32205740
[TBL] [Abstract][Full Text] [Related]
32. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
[TBL] [Abstract][Full Text] [Related]
33. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
[TBL] [Abstract][Full Text] [Related]
37. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
[TBL] [Abstract][Full Text] [Related]
38. Helicobacter pylori infection and PD-L1 expression in gastric cancer: A meta-analysis.
Zhu Y; Zhu F; Ba H; Chen J; Bian X
Eur J Clin Invest; 2023 Feb; 53(2):e13880. PubMed ID: 36164962
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.
Lu X; Li Y; Yang W; Tao M; Dai Y; Xu J; Xu Q
J Biochem Mol Toxicol; 2021 Jan; 35(1):e22621. PubMed ID: 32894642
[TBL] [Abstract][Full Text] [Related]
40. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]